← Anika Therapeutics, Inc. (ANIK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Anika Therapeutics, Inc. (ANIK)
Surgical & Medical Instruments & Apparatus · market cap $273M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Anika Therapeutics (ANIK) is a small-cap med-device/biopharma hybrid (~$208M market cap, 288 employees) focused on joint health, with two Phase 3 assets — Cingal and Triamcinolone Hexacetonide — both targeting knee osteoarthritis. Revenue has declined from $167M in 2023 to $113M in 2025, and the company has been unprofitable for four consecutive years, though net losses have narrowed from -$83M to -$11M.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Cingal | Phase 3 | Osteoarthritis, Knee |
| Triamcinolone Hexacetonide | Phase 3 | Knee Osteoarthritis |
Price & technical context
3-month
+26.0%
6-month
+29.2%
12-month
+106.0%
52-wk range
$9.02–$22.03
vs 50-day MA
-4.2%
vs 200-day MA
+29.7%
Realized vol
48.8%
Max drawdown
-68.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ANIK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.